Details of the Drug Reposition

General Information of This Drug (ID: DMGB035)

Drug Name
Armodafinil   DMGB035
Synonyms
Nuvigil; 112111-43-0; (R)-Modafinil; (R)-(-)-Modafinil; CEP-10953; UNII-V63XWA605I; CRL 40982; CEP 10953; V63XWA605I; CHEMBL1201192; CHEBI:77590; 2-[(R)-(Diphenylmethyl)sulfinyl]acetamide; (-)-2-((R)-(Diphenylmethyl)sulfinyl)acetamide; (-)-2-[(r)-(diphenylmethyl)sulfinyl]acetamide; Armodafinil [USAN:INN]; armodafinilo; armodafinilum; l-Modafinil; Nuvigil (TN); (-)-(R)-modafinil; Armodafinil (USAN/INN); SCHEMBL34489; ZINC6156; ACE037; Armodafinil, > YFGHCGITMMYXAQ-LJQANCHMSA-N
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL

Information on Drug Reposition of This Drug

Molecular Interaction Atlas (MIA)
6 Approved Indication(s)
Indication Name Indication ID ICD-11 Status REF
Postpoliomyelitis syndrome DISEG262 N.A. Approved [1]
Malignant glioma DISFXKOV 2A00.0 Approved [1]
Methamphetamine dependence DIS1UU1B 6C46.2 Approved [1]
Narcolepsy DISLCNLI 7A20 Approved [1]
Pain DIS4RWOW MG30-MG3Z Approved [1]
Traumatic brain injury DISN8K9H NA07.Z Approved [1]
------------------------------------------------------------------------------------
⏷ Show the Full List of 6 Indications(s)
1 Discontinued in Phase 2 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Malignant neoplasm DISS6SNG 2A00-2F9Z Discontinued in Phase 2 [2]
------------------------------------------------------------------------------------

References

1 Armodafinil FDA Label
2 Predictive Biomarkers of Response to Sunitinib in the Treatment of Poorly-differentiated NEURO-Endocrine Tumors